The Hellenic Atherosclerosis Society guidelines on dyslipidemia management – 2023

Lipoprotein(a) Assessment is recommended for measuring Lp(a) levels at least once during a person’s lifetime. Lp(a) testing should be considered for reclassifying patients with borderline estimated 10-year ASCVD risk.

Management of dyslipidemia in the elderly

• Lipid-lowering therapy should target LDL-C levels of: <55 mg/dL for very high-risk patients; <70 mg/dL for high-risk patients; and <100 mg/dL for moderate-risk patients (for individuals ≤75 years old).
• A reduction in LDL-C of more than 50% from baseline is advised for very high- and high-risk elderly patients aged ≤75 years.
• In elderly individuals over 75 years of age with very high or high risk, initiation of statin therapy should be considered (Class IIa).
• For elderly patients with renal impairment or those at risk of drug interactions, statin therapy should start at a low dose and be titrated as needed to achieve LDL-C targets.

Source: Katsiki N, Filippatos T, Vlachopoulos C, et al. Atheroscler Plus. 2024;55:74-92. Published 2024 Feb 17. doi:10.1016/j.athplu.2024.01.004